188 related articles for article (PubMed ID: 29983407)
1. Early Direct Antiglobulin Test Negativity after Bendamustine and Rituximab Treatment in Chronic Lymphocytic Leukemia: Two Cases.
Eren R; Suyanı E
Turk J Haematol; 2018 Nov; 35(4):312-313. PubMed ID: 29983407
[No Abstract] [Full Text] [Related]
2. Autoimmune hemolytic anemia during bendamustine plus rituximab treatment in CLL patients: multicenter experience.
Laurenti L; Autore F; Innocenti I; D'Arena G; Coscia M; Mondello P; Chiusolo P; Bellesi S; Efremov DG; Sica S; Mauro FR
Leuk Lymphoma; 2016 Oct; 57(10):2429-31. PubMed ID: 26818825
[No Abstract] [Full Text] [Related]
3. Bendamustine and Rituximab Treatment, Chronic Lymphocytic Leukemia, Direct Antiglobulin Test, and False Negatives.
Sriwijitalai W; Wiwanitkit V
Turk J Haematol; 2019 Feb; 36(1):53-54. PubMed ID: 30468431
[No Abstract] [Full Text] [Related]
4. Establishment of a comprehensive chronic lymphocytic leukemia clinic at a tertiary referral center in India.
Lad DP; Tejaswi V; Malhotra P; Varma N; Sachdeva MS; Naseem S; Sreedharanunni S; Prakash G; Khadwal A; Varma S
Blood Adv; 2018 Nov; 2(Suppl 1):33-34. PubMed ID: 30504196
[No Abstract] [Full Text] [Related]
5. Routine Use of Bendamustine in Patients with Chronic Lymphocytic Leukemia: An Observational Study.
Ninkovic M; Fiegl M; Mian M; Mondello P; Kocher F; Waldthaler C; Verdorfer I; Steurer M; Gastl G; Pircher A
Anticancer Res; 2015 Sep; 35(9):5129-39. PubMed ID: 26254418
[TBL] [Abstract][Full Text] [Related]
6. Rituximab/Bendamustine treatment of chronic lymphatic leukemia leads to sustained remission of antiphospholipid antibodies.
Ames PR; Merashli M; Gentile F
Eur J Immunol; 2019 Jun; 49(6):969-970. PubMed ID: 30893471
[No Abstract] [Full Text] [Related]
7. Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
Seymour JF; Kipps TJ; Eichhorst B; Hillmen P; D'Rozario J; Assouline S; Owen C; Gerecitano J; Robak T; De la Serna J; Jaeger U; Cartron G; Montillo M; Humerickhouse R; Punnoose EA; Li Y; Boyer M; Humphrey K; Mobasher M; Kater AP
N Engl J Med; 2018 Mar; 378(12):1107-1120. PubMed ID: 29562156
[TBL] [Abstract][Full Text] [Related]
8. Mixed-type autoimmune hemolytic anemia following fludarabine treatment in a patient with chronic lymphocytic leukemia/small cell lymphoma.
Vick DJ; Byrd JC; Beal CL; Chaffin DJ
Vox Sang; 1998; 74(2):122-6. PubMed ID: 9501412
[TBL] [Abstract][Full Text] [Related]
9. Fludarabine-associated autoimmune hemolytic anemia occurring in B-cell chronic lymphocytic leukemia.
Nishida H; Murase T; Ueno H; Park JW; Yano T; Ikeda Y
Leuk Res; 2006 Dec; 30(12):1589-90. PubMed ID: 16542723
[TBL] [Abstract][Full Text] [Related]
10. First reported association of chronic lymphocytic leukaemia and interstitial granulomatous dermatitis.
Riaz IB; Kamal MU; Segal RJ; Anwer F
BMJ Case Rep; 2016 May; 2016():. PubMed ID: 27194675
[TBL] [Abstract][Full Text] [Related]
11. A phase I dose-ranging study of bendamustine and rituximab in chronic lymphocytic leukemia patients with comorbidities.
Danilov AV; Lewis LD; Lansigan F; Roudaia L; Findley DL; Jones SY; Highhouse B; Beaulieu BB; Brown JR
Br J Haematol; 2017 Sep; 178(5):820-823. PubMed ID: 27377970
[No Abstract] [Full Text] [Related]
12. Effective treatment with rituximab in a patient with refractory prolymphocytoid transformed B-chronic lymphocytic leukemia and Evans syndrome.
Seipelt G; Böhme A; Koschmieder S; Hoelzer D
Ann Hematol; 2001 Mar; 80(3):170-3. PubMed ID: 11320903
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials.
Morabito F; Tripepi G; Del Poeta G; Mauro FR; Reda G; Sportoletti P; Laurenti L; Coscia M; Herishanu Y; Bossio S; Varettoni M; Murru R; Chiarenza A; Visentin A; Condoluci A; Moia R; Pietrasanta D; Loseto G; Consoli U; Scortechini I; Rossi FM; Zucchetto A; Al-Janazreh H; Vigna E; Martino EA; Cassin R; D Arrigo G; Galimberti S; Rago A; Angeletti I; Biagi A; Del Giudice I; Bomben R; Neri A; Fronza G; Monti P; Menichini P; Olivieri J; Cutrona G; Rossi D; Cuneo A; Di Raimondo F; Gaidano G; Polliack A; Trentin L; Foà R; Ferrarini M; Gattei V; Gentile M
Am J Hematol; 2021 Aug; 96(8):E269-E272. PubMed ID: 33878220
[No Abstract] [Full Text] [Related]
14. Bendamustine and rituximab combination in the management of chronic lymphocytic leukemia-associated autoimmune hemolytic anemia: a multicentric retrospective study of the French CLL intergroup (GCFLLC/MW and GOELAMS).
Quinquenel A; Willekens C; Dupuis J; Royer B; Ysebaert L; De Guibert S; Michallet AS; Feugier P; Guieze R; Levy V; Delmer A
Am J Hematol; 2015 Mar; 90(3):204-7. PubMed ID: 25428829
[TBL] [Abstract][Full Text] [Related]
15. The Direct Antiglobulin Test for Evaluating Anemia.
Eule C; Gupta A; Nagalla S
JAMA; 2018 Dec; 320(24):2593-2594. PubMed ID: 30508030
[No Abstract] [Full Text] [Related]
16. [Autoimmune hemolytic anemia, complement-mediated by warm reactive antibodies, associated with lymphoma].
Gallurt P; Oyonarte S; Gil JL; Senra A; Millán J
Rev Clin Esp; 1988 Nov; 183(7):383. PubMed ID: 3062716
[No Abstract] [Full Text] [Related]
17. Prospective observational study in comorbid patients with chronic lymphocytic leukemia receiving first-line bendamustine with rituximab.
Špaček M; Obrtlíková P; Hrobková S; Cmunt E; Karban J; Molinský J; Šimkovič M; Mociková H; Mohammadová L; Panovská A; Novák J; Trněný M; Smolej L; Doubek M
Leuk Res; 2019 Apr; 79():17-21. PubMed ID: 30797139
[TBL] [Abstract][Full Text] [Related]
18. Ofatumumab in rituximab-refractory autoimmune hemolytic anemia associated with chronic lymphocytic leukemia: a case report and review of literature.
Nader K; Patel M; Ferber A
Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):511-3. PubMed ID: 23726016
[No Abstract] [Full Text] [Related]
19. Marginal zone lymphoma-associated antiphospholipid antibodies successfully treated with bendamustine rituximab.
Liu Z; Markham M; Mandernach MW
BMJ Case Rep; 2019 Mar; 12(3):. PubMed ID: 30872333
[TBL] [Abstract][Full Text] [Related]
20. [Efficacy and safety of BTK inhibitor combined with bendamustine and rituximab in the first-line treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma].
Qin SC; Jiang R; Sha YQ; Qiu JY; Mi HL; Miao Y; Wu W; Wang L; Fan L; Xu W; Li JY; Zhu HY
Zhonghua Xue Ye Xue Za Zhi; 2023 Feb; 44(2):158-161. PubMed ID: 36948873
[No Abstract] [Full Text] [Related]
[Next] [New Search]
